Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions

Supportive Care in Cancer

Volumn 21, Issue 3, 2013, Pages 907-911

  Li, Jian Ri ^a,c   Yang, Chi Rei ^b   Cheng, Chen Li ^a   Ho, Hao Chung ^a   Chiu, Kun Yuan ^a   Su, Chung Kuang ^a   Chen, Wen Ming ^a   Wang, Shian Shiang ^a   Chen, Chuan Shu ^a   Yang, Cheng Kuang ^a   Ou, Yen Chuan ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hand foot skin reactions; Heparin; Multikinase inhibitor; Renal cell carcinoma

Indexed keywords

AXITINIB; HEPARIN; SORAFENIB; SUNITINIB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; HUMIDIFIER; KIDNEY METASTASIS; MALE; MULTIKINASE INHIBITOR-INDUCED HAND-FOOT SKIN REACTION; PALLIATIVE THERAPY; PRIORITY JOURNAL; SKIN MANIFESTATION; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HAND-FOOT SYNDROME; HEPARIN; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; MALE; MIDDLE AGED; NIACINAMIDE; OINTMENTS; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRROLES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84874109107     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1693-3     Document Type: Article

References (23)

1. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
2. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007(356):125-134
3. Rini BI, Wilding G, Hudes G et al (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468
4. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW (2006) Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24:5786-5788
5. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084-1096
6. Bhojani N, Jeldres C, Patard JJ et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917-930
7. Tomita Y, Shinohara N, Yuasa T et al (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166-1172
8. Zhang H, Dong B, Lu JJ et al (2009) Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9:249
9. Lee WJ, Lee JL, Chang SE et al (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161:1045-1051
10. Di Lorenzo G, Porta C, Bellmunt J et al (2011) Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59:526-540
11. Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A (2010) Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 28:856-864
12. Manchen E, Robert C, Porta C (2011) Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 9:13-23
13. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
14. Peplow PV (2005) Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds. Thromb Haemost 94:4-16
15. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
16. Di Lorenzo G, Autorino R, Sternberg CN (2009) Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 56:959-971
17. Rini BI (2009) Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 27:3225-3234
18. Saylor PJ, Michaelson MD (2009) New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 7:645-656
19. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
20. Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11-19
21. Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-1289
22. Yang CH, Lin WC, Chuang CK et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592-596
23. Oremus M, Hanson MD, Whitlock R et al (2007) A systematic review of heparin to treat burn injury. J Burn Care Res 28:794-804